Derbicil 1% (Cream)
5 gm tube: ৳ 50.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Terbinafine hydrochloride |
| Company | Incepta pharmaceuticals ltd |
| Also available as |
Title
- Derbicil Tablet
- Derbicil Granules
- Derbicil Cream
- Derbicil 1% Spray
Categories
- Antifungal Medicine
- Oral Medication
- Topical Medication
- Antifungal Spray
- Antifungal Granules
Description
- Indicated for the treatment of onychomycosis
- Inhibits biosynthesis of Ergosterol
- Dosage and administration instructions available
- Interaction with CYP450 2D6 isozyme
- Contraindicated for individuals with hypersensitivity to terbinafine
- Various side effects reported
- Use not recommended in pregnancy and lactation
- Precautions and warnings provided
- Limited clinical experience in pediatric patients
- Storage conditions specified
Dimensions
Color
Options
- Dosage & Administration:
- For the treatment of fingernail onychomycosis: Terbinafine 250 mg (one tablet), once daily for 6 weeks
- For the treatment of toenail onychomycosis: Terbinafine 250 mg (one tablet), once daily for 12 weeks
- Terbinafine cream can be applied once or twice daily
- Terbinafine 1% Spray is applied once or twice daily, depending on the indication
- Pharmacology:
- Inhibits biosynthesis of Ergosterol via inhibition of Squalene Epoxidase enzyme
- Fungicidal depending on drug concentration and fungal species
- Interaction:
- Inhibitor of the CYP450 2D6 isozyme
- May require reduction in dose of 2D6-metabolized drugs
- Contraindications:
- Contra-indicated in individuals with hypersensitivity to terbinafine
- Side Effects:
- Gastrointestinal symptoms
- Liver test abnormalities
- Rashes
- Urticaria
- Taste disturbances
- Idiosyncratic and symptomatic hepatic injury
- Serious skin reactions
- Severe neutropenia
- Thrombocytopenia
- Angioedema
- Allergic reactions
- Malaise
- Fatigue
- Vomiting
- Arthralgia
- Myalgia
- Hair loss
- Pregnancy & Lactation:
- Not recommended during pregnancy
- Excreted in breast milk
- Precautions & Warnings:
- Rare cases of liver failure reported
- Discontinue treatment if there is biochemical or clinical evidence of liver injury
- Avoid contact with eyes for Derbicil cream
- Not recommended for patients with chronic or active liver disease
- Pre-existing liver disease should be assessed before prescribing
- Pretreatment serum transaminase tests advised for all patients before taking terbinafine tablets
- Overdose Effects:
- Limited clinical experience regarding overdose with terbinafine tablets
- Symptoms include nausea, vomiting, abdominal pain, dizziness, rash, frequent urination, headache
- Storage Conditions:
- Store in a cool and dry place
- Below 30°C
- Protect from light